Trial Scorecards

Trial Scorecard: MARINER

Researchers compared rivaroxaban (Xarelto, Janssen) with placebo to prevent symptomatic venous thromboembolism and VTE death after hospital discharge in patients who were medically ill and at high risk for VTE.

Trial Scorecard: MARINER

Researchers compared rivaroxaban (Xarelto, Janssen) with placebo to prevent symptomatic venous thromboembolism and VTE death after hospital discharge in patients who were medically ill and at high risk for VTE.

Trial Scorecard: MARINER